|
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen
European Journal of Haematology, February 2009
Click here to view the abstract
A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Clinical Cancer Research, February 2009
Click here to view the abstract
A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Clinical Cancer Research, March 2007
Click here to view abstract
Efficacy and Safety of Melphalan, Arsenic Trioxide and Ascorbic Acid Combination Therapy in Patients with Relapsed or Refractory Multiple Myeloma: a Prospective, Multicentre, Phase II, Single-Arm Study
British Journal of Haematology, October 2006
Click here to view abstract
A Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Journal of Clinical Oncology, February 2006
Click here to view abstract
| 
